Pre-clinical trial demonstrated high safety profile in addition to a significant suppressive effect on alcohol consumption VANCOUVER, May 19, 2022 (GLOBE NEWSWIRE)...
REDWOOD CITY, Calif., May 19, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting...
ASHEVILLE, N.C., May 19, 2022 (GLOBE NEWSWIRE) -- ADC, a leading cannabis distribution company, announced a partnership with Alt Magic...
Collaboration to create a synergistic treatment offering, combining BioCorRx’s MAT treatment program and 2B3D virtual reality technology Plans toward expanding...
CAMBRIDGE, Mass., May 19, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”) a biopharmaceutical company focused on developing...
BALA CYNWYD, Pa., May 19, 2022 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused...
OAK BROOK, Ill., May 19, 2022 (GLOBE NEWSWIRE) -- Sterigenics®, a business of Sotera Health, and a global leader in...
BMF-500, an investigational third-generation covalent inhibitor of FLT3, demonstrated picomolar IC50 values across key FLT3 isoforms, potentially making it the...
Enrollment in the CERPASS clinical trial with RP1 in cutaneous squamous cell carcinoma (CSCC) expected to be completed in mid-year...
Nes-Ziona, Israel, May 19, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy...
– BBI-02 is a potential first-in-class, oral DYRK1A inhibitor with strong preclinical validation and broad potential to treat debilitating autoimmune...
BATON ROUGE, La., May 19, 2022 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), a leading provider of home health, hospice,...
Durable and clinically meaningful responses sustained for more than three years post-treatment in study of DTX401 for GSDIa and four...
DUBLIN, Ireland, May 19, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines...
MENLO PARK, Calif., May 19, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) an eyecare technology company focused on...
OXFORD, United Kingdom, May 19, 2022 (GLOBE NEWSWIRE) -- Evox Therapeutics Ltd (‘Evox’ or the ‘Company’), a leading exosome therapeutics...
UB-VV100 preclinical safety data demonstrates overall low risk for off target transduction and has a favorable safety and biodistribution profile...
PORTLAND, Maine, May 19, 2022 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company...
OCALA, Fla., May 19, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma...
Independent Data Monitoring Committee advises continuation of trial without modification No safety or tolerability concerns observed in the first two...